Across TCGA pan-cancer cohorts, MT1M mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MT1M data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MT1M mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MT1M expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where MT1M mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.840	0.659	.008	30	view →
CCRCC	OS	Median	All	1.000	0.747	.008	9	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.233	.011	8	view →
PDAC	OS	Median	III,IV	0.912	0.612	.007	7	view →
GBM	OS	Median	All	0.456	0.580	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MT1M tumor-vs-normal RNA expression · all MT1M data types